Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes

Kyle R Gibson, Tim J Winterburn, Fiona Barrett, Sushma Sharma, Sandra M MacRury, Ian L Megson

Research output: Contribution to journalArticle

31 Citations (Scopus)


Platelet hyperaggregability is a pro-thrombotic feature of type-2 diabetes, associated with low levels of the antioxidant glutathione (GSH). Clinical delivery of N-acetylcysteine (NAC), a biosynthetic precursor of GSH, may help redress a GSH shortfall in platelets, thereby reducing thrombotic risk in type-2 diabetes patients. We investigated the effect of NAC in vitro, at concentrations attainable with tolerable oral dosing, on platelet GSH concentrations and aggregation propensity in blood from patients with type-2 diabetes.
Original languageEnglish
Pages (from-to)43
JournalCardiovascular Diabetology
Publication statusPublished - 2011


Cite this